Highlights of the Program

2 days business program:

Learn from real-world case studies by industry leaders.

SHOWCASING INNOVATION:

Discover the latest technology and techniques from across the industry.

leaders talk:

Hear from top-level experts about how to stay ahead in a fast-changing industry.

MULTIPLE STREAMS:

A business program that is multi-disciplinary, giving you a broad view of the industry.

SMART TECHNOLOGIES:

Explore the latest smart and AI-driven solutions, and see how they can be used in your business.

roundtable discussion:

Join talks with industry peers. Share ideas, make connections, and find new partners.

Program

Day 1 :

WEDNESDAY, APRIL 29, 2026

08:30 - 09:30

REGISTRATION AND MORNING REFRESHMENTS

09:30 - 09:40

OPENING ADDRESS

09:40 - 10:05

GUT MICROBIAL METABOLITES AS MODULATORS OF NEUROINFLAMMATION IN ALZHEIMER’S DISEASE

Vasu Gautam

Norton Healthcare

Investigating gut metabolites that modulate neuroinflammation and amyloid, shaping therapy in AD
Identifying specific metabolites and mapping their linkage to defined gut microbes in AD
Proposing customizable probiotics for Alzheimer’s patients using metabolite–microbe signals

10:05 - 10:10

Q&A SESSION ON GUT METABOLITES AND ALZHEIMER’S DISEASE

10:10 - 10:40

SPEED NETWORKING SESSION

Exchange business cards and get connected in short one-to-one meetings
Start the conversation to arrange a more formal meeting later on in the conference
Share your professional background and discuss your biggest business issues – don't forget your business cards

10:40 - 11:00

MORNING COFFEE BREAK IN THE EXHIBIT AREA

11:00 - 11:30

PANEL DISCUSSION ON METABOLIC MEDICINE

11:30 - 11:55

OPTIMIZING GLP-1 AGONIST THERAPY THROUGH METHYLATION PATHWAY ASSESSMENT

Charles Sailey

Molecular Testing Labs

Introducing gene-guided GLP-1 optimization using methylation variants like MTHFR and COMT
Enhancing metabolic outcomes by correcting inefficiencies in one-carbon nutrient pathways
Demonstrating improved GLP-1 efficacy and detox response through precision supplementation

11:55 - 12:00

Q&A SESSION ON PRECISION GENETICS AND GLP-1 RESPONSE

12:00 - 13:30

NETWORKING LUNCH AND VISITING THE OBESITY MEDICINE EXHIBITION

13:30 - 13:55

THE MIND/BODY PROBLEM – METABOLIC SYNDROME AND COGNITIVE DECLINE

Steve Winshel

FULLFILL

Clarifying the strong links between metabolic dysfunction and cognitive impairments
Highlighting complications due to the late detection of cognitive decline in patients
Showcasing innovative early detection tools to prevent irreversible brain changes
Integrating mind-body approaches to address both metabolic and cognitive issues

13:55 - 14:00

Q&A SESSION ON LINKING METABOLISM AND BRAIN HEALTH

14:00 - 14:25

IMPROVING ARRHYTHMIA MANAGEMENT THROUGH EARLY DETECTION IN COMORBID PATIENTS (T2DM, CKD, CAD, COPD)

Joe Valderas

iRhythm Technologies, Inc.

Leveraging EMR-based AI to identify high-risk comorbid patients earlier and reduce ER visits
Highlighting limits of symptom-led screening, with 18% rhythm correlation in 1.1M patients
Quantifying diagnostic overshadowing, with only one in four escalated to cardiac monitoring

14:25 - 14:30

Q&A SESSION ON EARLY ARRHYTHMIA DETECTION IN COMORBIDITY

14:30 - 15:00

AFTERNOON COFFEE BREAK IN THE EXHIBIT AREA

15:00 - 15:25

UNLOCKING NATURAL WEIGHT-REGULATING BIOLOGY THROUGH LEPTIN SENSITIZATION

Teo Uysal

ERX Pharmaceuticals

Delving into leptin's pivotal role in weight regulation and obesity treatment
Uncovering unique biological mechanisms for enhanced efficacy and muscle preservation
Presenting promising initial findings from a Phase 1 study of a novel leptin sensitizer

15:25 - 15:30

Q&A SESSION ON LEPTIN SENSITIZATION IN OBESITY TREATMENT

15:30 - 15:55

ENABLING DEVICE SOLUTIONS FOR UNMET NEEDS IN BIOTHERAPIES

Asmita Khanolkar

SMC® Ltd.

Highlighting novel methods for drug-device-delivery optimization and assessment
Introducing an autoinjector simulator to evaluate pharmacokinetics and dynamics
Accelerating early evaluation and speed to clinics for biologics with unique needs

15:55 - 16:00

Q&A SESSION ON ENABLING DEVICE SOLUTIONS IN BIOTHERAPIES

16:00 - 16:25

MAPPING THE HUMAN ENZYME–METABOLITE INTERACTOME TO UNCOVER MECHANISMS OF METABOLIC REGULATION, DISEASE, AND THERAPEUTIC OPPORTUNITIES

Kevin Hicks

University of Utah

Mapping enzyme–metabolite interactions (EMIs) with MIDAS to reveal metabolic regulation and disease
Combining equilibrium dialysis and LC–MS to discover ligands for soluble and membrane proteins
Showcasing novel EMI networks and allosteric regulators with therapeutic potential

16:25 - 16:30

Q&A SESSION ON THE HUMAN ENZYME–METABOLITE INTERACTOME

16:30 - 17:30

NETWORKING DRINKS RECEPTION

Day 2 :

THURSDAY, APRIL 30, 2026

09:00 - 09:30

MORNING REFRESHMENTS

09:30 - 09:40

OPENING ADDRESS

09:40 - 10:05

ENSURING ACCESS AND SUPPORT IN OBESITY CARE

Sansei Fowler

CVS Health

Enhancing patient access to obesity treatments through optimal payer coverage strategies
Coordinating care models for GLP-1 therapy for comprehensive support to improved outcomes
Forecasting future trends in obesity treatment by analyzing drug pipelines and the role of PBMs in care

10:05 - 10:10

Q&A SESSION ON THE ACCESS AND SUPPORT IN OBESITY TREATMENT

10:10 - 10:35

NA-931: AN ORAL QUADRUPLE RECEPTOR AGONIST FOR WEIGHT LOSS WITHOUT MUSCLE LOSS

Lloyd Tran

Biomed Industries, Inc.

Describing the mechanism of action of this oral quadruple receptor agonist
Summarizing topline Phase 1 and Phase 2 clinical trial results on the safety and efficacy of NA-931
Reporting significant weight loss with no muscle loss or major GI-related adverse events

10:35 - 10:40

Q&A SESSION ON NA-931 AND ADVANCES IN WEIGHT MANAGEMENT

10:40 - 11:10

RESERVED PRESENTATION

11:10 - 11:30

MORNING COFFEE BREAK IN THE EXHIBIT AREA

11:30 - 11:55

AI-ENABLED METABOLOMICS: A NEW ERA FOR BIOMARKER DISCOVERY AND PRECISION HEALTH

Aviral Singh

Clarity Bio Systems

Unifying LC-HRMS with automated QQQ and GC–MS to shorten metabolomics turnaround time
Employing AutoML and explainable AI for robust biomarker selection and clear biology insight
Analyzing diabetes (400+) and marathon (150+) cohorts to reveal actionable metabolic signatures
Establishing a scalable, reproducible framework to translate metabolomics into clinical use

11:55 - 12:00

Q&A SESSION ON AI-ENABLED METABOLOMICS FOR BIOMARKERS

12:00 - 12:25

EXPLORING INNOVATIVE TECHNOLOGIES IN THE FIGHT AGAINST OBESITY

Ashley Zehnder

Fauna Bio

Discussing rising global obesity rates and the urgent need for innovative solutions
Examining the role of muscle-preserving agents in improving metabolic health during weight loss
Highlighting recent technological and biomedical advancements in obesity treatment strategies

12:25 - 12:30

Q&A SESSION ON USING MUSCLE PRESERVATION FOR OBESITY TREATMENTS

12:30 - 12:55

DATA-DRIVEN METABOLIC RESET - A 90 DAY PROGRAM FOR LIFELONG WELLNESS

Harris Masket

Jyzen

Personalizing a 90-day metabolic reset with advanced labs, metabolic testing, and wearables
Optimizing therapeutics with customized peptides, supplements, nutrition, and training plans
Measuring and sharing program data from labs and wearables that demonstrate metabolic gains

12:55 - 13:00

Q&A SESSION ON DATA-DRIVEN METABOLIC RESET

13:00 - 13:25

REWIRING BIOLOGY: GLP-1 RECEPTOR AGONIST AS THERAPIES FOR ADDICTION AND CRAVING CONTROL

Steven Klein

Caron Treatment Centers

Modulating metabolic and neural reward circuits with GLP-1 receptor agonists for craving control
Drawing insights from residential treatment, recovery, and criminal justice re-entry cohorts
Shaping future directions in neuroimaging, long-term care, and precision addiction therapy

13:25 - 13:30

Q&A SESSION ON GLP-1 THERAPIES FOR ADDICTION CONTROL

13:30 - 13:45

FEEDBACK & RAFFLE DRAW

13:45 - 15:00

NETWORKING LUNCH

Become a Speaker & Join the Conversation

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.